Who owns RECURSION PHARMACEUTICALS, INC.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of RXRX from SEC Form 13F filings across 352 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 352 institutions disclosed 388.2M shares of RECURSION PHARMACEUTICALS, INC. worth $1.60B — about 71.5% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
352
13F holders
$1.60B
value, 2026 filers
71.5%
of shares outstanding (388.2M sh)
63
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of RXRX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 53.5M | $220.9M | 0.0% | 9.8% | +6.3% |
| 2 | ARK Investment Management LLC | 44.7M | $184.8M | 1.1% | 8.2% | +8.2% |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 35.8M | $147.9M | 0.0% | 6.6% | +15.0% |
| 4 | STATE STREET CORP | 30.0M | $123.9M | 0.0% | 5.5% | -13.6% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 23.0M | $95.0M | 0.0% | 4.2% | +1.0% |
| 6 | BAILLIE GIFFORD & CO | 18.2M | $75.1M | 0.1% | 3.3% | -22.6% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 13.9M | $57.5M | 0.0% | 2.6% | +0.7% |
| 8 | SOFTBANK GROUP CORP. | 13.6M | $56.3M | 0.3% | 2.5% | 0.0% |
| 9 | FMR LLC | 11.4M | $47.2M | 0.0% | 2.1% | +24577.8% |
| 10 | UBS Group AG | 8.4M | $34.8M | 0.0% | 1.6% | -5.8% |
| 11 | MIC Capital Management UK LLP | 8.3M | $34.1M | 7.4% | 1.5% | -14.4% |
| 12 | TWO SIGMA INVESTMENTS, LP | 8.0M | $32.8M | 0.0% | 1.5% | +137.1% |
| 13 | MORGAN STANLEY | 6.2M | $25.7M | 0.0% | 1.1% | +126.9% |
| 14 | Data Collective IV GP, LLC | 5.9M | $24.5M | 38.8% | 1.1% | 0.0% |
| 15 | PRICE T ROWE ASSOCIATES INC /MD/ | 5.7M | $23.6M | 0.0% | 1.1% | +695.1% |
| 16 | Sumitomo Mitsui Trust Group, Inc. | 4.9M | $20.4M | 0.0% | 0.9% | -10.3% |
| 17 | Amova Asset Management Americas, Inc. | 4.9M | $20.4M | 0.3% | 0.9% | -10.3% |
| 18 | GMT Capital CorpNEW | 4.9M | $20.1M | 0.9% | 0.9% | new |
| 19 | NORTHERN TRUST CORP | 4.8M | $19.9M | 0.0% | 0.9% | +1.3% |
| 20 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 4.7M | $19.6M | 0.0% | 0.9% | +14.7% |
| 21 | MILLENNIUM MANAGEMENT LLC | 4.0M | $16.7M | 0.0% | 0.7% | +120.5% |
| 22 | DCVC Opportunity Fund II GP, LLC | 4.0M | $16.3M | 88.0% | 0.7% | 0.0% |
| 23 | FIRST TRUST ADVISORS LP | 3.6M | $14.7M | 0.0% | 0.7% | +16.8% |
| 24 | VANGUARD FIDUCIARY TRUST CO | 3.5M | $14.6M | 0.0% | 0.7% | +1.9% |
| 25 | GOLDMAN SACHS GROUP INC | 3.2M | $13.3M | 0.0% | 0.6% | -18.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.